These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

88 related items for PubMed ID: 6622816

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Inhibition of oxidative drug metabolism by orphenadrine: in vitro and in vivo evidence for isozyme-specific complexation of cytochrome P-450 and inhibition kinetics.
    Reidy GF, Mehta I, Murray M.
    Mol Pharmacol; 1989 May; 35(5):736-43. PubMed ID: 2725477
    [Abstract] [Full Text] [Related]

  • 3. Effect of multiple administration of orphenadrine or mono-N-desmethylorphenadrine on cytochrome P-450 catalyzed reactions in the rat.
    Bast A, Savenije-Chapel EM, van Kemenade FA, Scheefhals LW, Noordhoek J.
    Arch Toxicol; 1983 Oct; 54(2):131-7. PubMed ID: 6651526
    [Abstract] [Full Text] [Related]

  • 4. Inhibition of mono-oxygenase and oxidase activity of rat-hepatic cytochrome P-450 by H2-receptor blockers.
    Bast A, Savenije-Chapel EM, Kroes BH.
    Xenobiotica; 1984 May; 14(5):399-408. PubMed ID: 6089451
    [Abstract] [Full Text] [Related]

  • 5. Relationship between molecular structure and cytochrome P450-metabolic intermediate complex formation, studied with orphenadrine analogues.
    Bast A, Savenije-Chapel EM, Noordhoek J.
    J Pharm Sci; 1984 Jul; 73(7):953-6. PubMed ID: 6470960
    [Abstract] [Full Text] [Related]

  • 6. Cytochrome P450 metabolic intermediate complex of nefopam.
    Leurs R, Donnell D, Timmerman H, Bast A.
    J Pharm Pharmacol; 1987 Oct; 39(10):835-7. PubMed ID: 2891822
    [Abstract] [Full Text] [Related]

  • 7. Interaction of constitutive and phenobarbital-induced cytochrome P-450 isozymes during the sequential oxidation of benzphetamine. Explanation for the difference in benzphetamine-induced hydrogen peroxide production and 455-nm complex formation in microsomes from untreated and phenobarbital-treated rats.
    Jeffery EH, Mannering GJ.
    Mol Pharmacol; 1983 May; 23(3):748-57. PubMed ID: 6865917
    [Abstract] [Full Text] [Related]

  • 8. NTP technical report on the toxicity and metabolism studies of chloral hydrate (CAS No. 302-17-0). Administered by gavage to F344/N rats and B6C3F1 mice.
    Beland FA.
    Toxic Rep Ser; 1999 Aug; (59):1-66, A1-E7. PubMed ID: 11803702
    [Abstract] [Full Text] [Related]

  • 9. Major isozymes of rat liver microsomal cytochrome P-450 involved in the N-oxidation of N-isopropyl-alpha-(2-methylazo)-p-toluamide, the azo derivative of procarbazine.
    Prough RA, Brown MI, Dannan GA, Guengerich FP.
    Cancer Res; 1984 Feb; 44(2):543-8. PubMed ID: 6692359
    [Abstract] [Full Text] [Related]

  • 10. Metabolic-intermediate complex formation reveals major changes in rat hepatic cytochrome P-450 subpopulations in addition to those forms previously purified after phenobarbital, beta-naphthoflavone, and isosafrole induction.
    Bornheim LM, Franklin MR.
    Mol Pharmacol; 1982 Mar; 21(2):527-32. PubMed ID: 7099151
    [Abstract] [Full Text] [Related]

  • 11. Effect of cimetidine on hepatic cytochrome P450: evidence for formation of a metabolite-intermediate complex.
    Levine M, Bellward GD.
    Drug Metab Dispos; 1995 Dec; 23(12):1407-11. PubMed ID: 8689952
    [Abstract] [Full Text] [Related]

  • 12. Enhanced rates of cytochrome P450 metabolic-intermediate complex formation from nonmacrolide amines in rifampicin-treated rabbit liver microsomes.
    Franklin MR.
    Drug Metab Dispos; 1995 Dec; 23(12):1379-82. PubMed ID: 8689947
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Spectral interaction of orphenadrine and its metabolites with oxidized and reduced hepatic microsomal cytochrome P-450 in the rat.
    Bast A, Noordhoek J.
    Biochem Pharmacol; 1982 Sep 01; 31(17):2745-53. PubMed ID: 7138571
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Involvement of cytochrome P-450IIIA in metabolism of potassium canrenoate to an epoxide: mechanism of inhibition of the epoxide formation by spironolactone and its sulfur-containing metabolite.
    Cook CS, Hauswald C, Oppermann JA, Schoenhard GL.
    J Pharmacol Exp Ther; 1993 Jul 01; 266(1):1-7. PubMed ID: 8331551
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Inactivation of cytochrome P-450 by a troleandomycin metabolite. Protective role of glutathione.
    Pessayre D, Tinel M, Larrey D, Cobert B, Funck-Brentano C, Babany G.
    J Pharmacol Exp Ther; 1983 Mar 01; 224(3):685-91. PubMed ID: 6600790
    [Abstract] [Full Text] [Related]

  • 19. Metabolism of the antimammary cancer antiestrogenic agent tamoxifen. I. Cytochrome P-450-catalyzed N-demethylation and 4-hydroxylation.
    Mani C, Gelboin HV, Park SS, Pearce R, Parkinson A, Kupfer D.
    Drug Metab Dispos; 1993 Mar 01; 21(4):645-56. PubMed ID: 8104124
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.